Sultan Sherif, Dulai Makinderjit, Laffey John, Clarkson Kevin, Abedi Abdelaly M A, Barrett Nora, Elsherif Mohamed, Tawfick Wael, Hynes Niamh
Department of Vascular and Endovascular Surgery, Western Vascular Institute, University Hospital Galway, National University of Ireland, Galway, Ireland; Department of Vascular and Endovascular Surgery, Galway Clinic, Royal College of Surgeons of Ireland/National University of Ireland Affiliated Teaching Hospital, Galway, Ireland.
Department of Vascular and Endovascular Surgery, Western Vascular Institute, University Hospital Galway, National University of Ireland, Galway, Ireland.
Ann Vasc Surg. 2020 Nov;69:163-173. doi: 10.1016/j.avsg.2020.05.041. Epub 2020 May 28.
The aim of this study is to establish the initial safety of triple neuroprotection (TNP) in an acute stroke setting in patients presenting outside the window for systemic tissue plasminogen activator (tPA).
Over 12,000 patients were referred to our vascular services with carotid artery disease, of whom 832 had carotid intervention with a stroke rate of 0.72%. Of these, 25 patients presented (3%), between March 2015 and 2019, with acute dense stroke. These patients had either failed tPA or passed the recommended timing for acute stroke intervention. Fifteen (60%) had hemi-neglect with evidence of acute infarct on magnetic resonance imaging of the brain and a Rankin score of 4 or 5. Ninety-six percent had an 80-99% stenosis on the symptomatic side. Mean ABCD3-I score was 11.35. All patients underwent emergency carotid endarterectomy (CEA) with therapeutically induced hypothermia (32-34°C), targeted hypertension (systolic blood pressure 180-200 mm Hg), and brain suppression with barbiturate.
There were no cases of myocardial infarction, death, cranial nerve injury, wound hematoma, or procedural bleeding. Mean hospital stay was 8.4 (±9.5) days. All cases had resolution of neurological symptoms, except 3 who had failed previous thrombolysis. Eighty percent had a postoperative Rankin score of 0 on discharge and 88% of patients were discharged home with 3 requiring rehabilitation.
Positive neurological outcomes and no serious adverse events were observed using TNP during emergency CEA in patients with acute brain injury. We recommend TNP for patients who are at an increased risk of stroke perioperatively, or who have already suffered from an acute stroke beyond the recommended window of 24 hr. Certainly, the positive outcomes are not likely reproducible outside of high-volume units and patients requiring this surgery should be transferred to experienced surgeons in appropriate tertiary referral centers.
本研究的目的是确定在急性卒中情况下,对于超出全身组织型纤溶酶原激活剂(tPA)治疗时间窗就诊的患者,三联神经保护(TNP)的初始安全性。
超过12000例患有颈动脉疾病的患者被转诊至我们的血管科,其中832例接受了颈动脉介入治疗,卒中发生率为0.72%。在这些患者中,25例(3%)在2015年3月至2019年期间出现急性致密性卒中。这些患者要么tPA治疗失败,要么超过了急性卒中干预的推荐时间。15例(60%)存在半侧忽视,脑部磁共振成像显示有急性梗死灶,改良Rankin量表评分为4或5分。96%的患者症状侧存在80% - 99%的狭窄。平均ABCD3 - I评分为11.35分。所有患者均接受了急诊颈动脉内膜切除术(CEA),并采用治疗性低温(32 - 34°C)、目标性高血压(收缩压180 - 200 mmHg)以及巴比妥类药物进行脑抑制。
未发生心肌梗死、死亡、脑神经损伤、伤口血肿或手术出血病例。平均住院时间为8.4(±9.5)天。除3例先前溶栓治疗失败的患者外,所有病例的神经症状均得到缓解。80%的患者出院时改良Rankin量表评分为0,88%的患者出院回家,3例需要康复治疗。
在急性脑损伤患者的急诊CEA手术中,使用TNP观察到了积极的神经学结果,且未发生严重不良事件。我们建议对围手术期卒中风险增加或已发生超出24小时推荐时间窗的急性卒中患者采用TNP。当然,在高容量医疗单位之外,这些积极结果不太可能重现,需要进行该手术的患者应转诊至合适的三级转诊中心,由经验丰富的外科医生进行治疗。